Cover Image
市場調查報告書

Phico Therapeutics Ltd.- 產品平台檢討

Phico Therapeutics Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256137
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Phico Therapeutics Ltd.- 產品平台檢討 Phico Therapeutics Ltd. - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 22 Pages
簡介

Phico Therapeutics Ltd.是總公司設在英國的製藥企業,進行醫療用的新抗生素的研究開發。該公司在臨床試驗的階段的產品,有對抗以MRSA為首黃色葡萄球菌(SASPject PT1.2)、綠色膿菌(SASPject PT3.1)、大腸菌和肺炎桿菌等抗性革蘭氏陰性菌的全身性抗生素(SASPject 有PT3.X)等。

本報告提供Phico Therapeutics Ltd.的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Phico Therapeutics Ltd.的基本資料

  • Phico Therapeutics Ltd.概要
  • 主要資訊
  • 企業資料

Phico Therapeutics Ltd.:R&D概要

  • 主要的治療範圍

Phico Therapeutics Ltd.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Phico Therapeutics Ltd.:開發中產品概況

  • 在臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Phico Therapeutics Ltd.:藥物簡介

  • PT-1.2
  • PT-3.1
  • PT-3.33
  • PT-4

Phico Therapeutics Ltd.:開發平台分析

  • 各給藥途徑
  • 各分子類型

Phico Therapeutics Ltd.:最近的開發平台資訊

Phico Therapeutics Ltd.:開發暫停中的計劃

Phico Therapeutics Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07126CDB

Summary

Global Markets Direct's, 'Phico Therapeutics Ltd. - Product Pipeline Review - 2015', provides an overview of the Phico Therapeutics Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Phico Therapeutics Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Phico Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Phico Therapeutics Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Phico Therapeutics Ltd.'s pipeline products

Reasons to buy

  • Evaluate Phico Therapeutics Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Phico Therapeutics Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Phico Therapeutics Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Phico Therapeutics Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Phico Therapeutics Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Phico Therapeutics Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Phico Therapeutics Ltd. Snapshot
    • Phico Therapeutics Ltd. Overview
    • Key Information
    • Key Facts
  • Phico Therapeutics Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Phico Therapeutics Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Phico Therapeutics Ltd. - Pipeline Products Glance
    • Phico Therapeutics Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Phico Therapeutics Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Phico Therapeutics Ltd. - Drug Profiles
    • PT-1.2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-3.1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-3.33
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PT-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Phico Therapeutics Ltd. - Pipeline Analysis
    • Phico Therapeutics Ltd. - Pipeline Products by Route of Administration
    • Phico Therapeutics Ltd. - Pipeline Products by Molecule Type
  • Phico Therapeutics Ltd. - Recent Pipeline Updates
  • Phico Therapeutics Ltd. - Dormant Projects
  • Phico Therapeutics Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Phico Therapeutics Ltd., Key Information
  • Phico Therapeutics Ltd., Key Facts
  • Phico Therapeutics Ltd. - Pipeline by Indication, 2015
  • Phico Therapeutics Ltd. - Pipeline by Stage of Development, 2015
  • Phico Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
  • Phico Therapeutics Ltd. - Phase I, 2015
  • Phico Therapeutics Ltd. - Preclinical, 2015
  • Phico Therapeutics Ltd. - Discovery, 2015
  • Phico Therapeutics Ltd. - Pipeline by Route of Administration, 2015
  • Phico Therapeutics Ltd. - Pipeline by Molecule Type, 2015
  • Phico Therapeutics Ltd. - Recent Pipeline Updates, 2015
  • Phico Therapeutics Ltd. - Dormant Developmental Projects,2015

List of Figures

  • Phico Therapeutics Ltd. - Pipeline by Top 10 Indication, 2015
  • Phico Therapeutics Ltd. - Pipeline by Stage of Development, 2015
  • Phico Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
  • Phico Therapeutics Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Phico Therapeutics Ltd. - Pipeline by Top 10 Molecule Type, 2015
Back to Top